metformin has been researched along with Schizophrenia in 56 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
Schizophrenia: A severe emotional disorder of psychotic depth characteristically marked by a retreat from reality with delusion formation, HALLUCINATIONS, emotional disharmony, and regressive behavior.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Clozapine, while effective in treatment refractory schizophrenia, is associated with significant weight gain, heart disease and increased risk of type 2 diabetes mellitus (T2DM)." | 9.27 | CoMET: a protocol for a randomised controlled trial of co-commencement of METformin as an adjunctive treatment to attenuate weight gain and metabolic syndrome in patients with schizophrenia newly commenced on clozapine. ( Baker, A; Flaws, D; Friend, N; Kisely, S; Lim, C; McGrath, JJ; Moudgil, V; Patterson, S; Russell, A; Sardinha, S; Siskind, D; Stedman, T; Suetani, S; Winckel, K, 2018) |
| "In this 12-week, randomized, double-blind, placebo-controlled trial, metformin at 500 mg/d or 1000 mg/d was prescribed to clozapine-treated patients with schizophrenia who had pre-existing metabolic abnormalities." | 9.22 | Effects of Low Dose Metformin on Metabolic Traits in Clozapine-Treated Schizophrenia Patients: An Exploratory Twelve-Week Randomized, Double-Blind, Placebo-Controlled Study. ( Chen, CH; Chen, PY; Chiu, CC; Huang, MC; Lin, SK; Lin, YK; Lu, ML, 2016) |
| " In this study, data were pooled from two randomized, placebo-controlled trials, which were originally designed to examine the efficacy of metformin in treating antipsychotic-induced weight gain and other metabolic abnormalities." | 9.22 | Metformin treatment of antipsychotic-induced dyslipidemia: an analysis of two randomized, placebo-controlled trials. ( Chan, PK; Gao, KM; Guo, WB; Jin, H; Ou, JJ; Shao, P; Wu, RR; Zhang, FY; Zhao, JP, 2016) |
| " We recruited patients with DSM-IV diagnosis of schizophrenia or schizoaffective disorder who had been taking clozapine for more than 3 months, were overweight or obese, or fulfilled at least 1 criteria of metabolic syndrome." | 9.17 | Effects of adjunctive metformin on metabolic traits in nondiabetic clozapine-treated patients with schizophrenia and the effect of metformin discontinuation on body weight: a 24-week, randomized, double-blind, placebo-controlled study. ( Chen, CH; Chiu, CC; Huang, MC; Kao, CF; Kuo, PH; Lin, SK; Lu, ML, 2013) |
| "Metformin was modestly effective in reducing weight and other risk factors for cardiovascular disease in clinically stable, overweight outpatients with chronic schizophrenia or schizoaffective disorder over 16 weeks." | 9.17 | Metformin for weight loss and metabolic control in overweight outpatients with schizophrenia and schizoaffective disorder. ( Catellier, DJ; Golden, LH; Hamer, RM; Jarskog, LF; Lavange, L; Lieberman, JA; Ray, N; Stewart, DD; Stroup, TS, 2013) |
| "Metformin was effective in reversing antipsychotic-induced adverse events, including restoration of menstruation, promotion of weight loss, and improvement in insulin resistance in female patients with schizophrenia." | 9.16 | Metformin for treatment of antipsychotic-induced amenorrhea and weight gain in women with first-episode schizophrenia: a double-blind, randomized, placebo-controlled study. ( Chan, PK; Davis, JM; Gao, K; Guo, XF; Jin, H; Ou, JJ; Shao, P; Twamley, EW; Wang, J; Wu, RR; Zhao, JP, 2012) |
| " The body weight, body mass index, fasting insulin and insulin resistance index decreased significantly in the metformin group, but increased in the placebo group during the 12-week follow-up period." | 9.16 | Metformin for treatment of antipsychotic-induced weight gain: a randomized, placebo-controlled study. ( Liang, GM; Tong, JH; Wang, M; Wang, XZ; Yan, HF; Zhu, G, 2012) |
| "Outpatients with schizophrenia or schizoaffective disorder (DSM-IV-TR criteria) were randomly assigned to olanzapine alone (n = 50), olanzapine plus algorithm A (olanzapine + A [amantadine 200 mg/d with possible switches to metformin 1,000-1,500 mg/d and then to zonisamide 100-400 mg/d; n = 76]), or olanzapine plus algorithm B (olanzapine + B [metformin 1,000-1,500 mg/d with possible switches to amantadine 200 mg/d and then to zonisamide 100-400 mg/d; n = 73])." | 9.16 | Assessment of treatment algorithms including amantadine, metformin, and zonisamide for the prevention of weight gain with olanzapine: a randomized controlled open-label study. ( Case, M; Hoffmann, VP; Jacobson, JG, 2012) |
| "Lifestyle intervention and metformin alone and in combination demonstrated efficacy for antipsychotic-induced weight gain." | 9.13 | Lifestyle intervention and metformin for treatment of antipsychotic-induced weight gain: a randomized controlled trial. ( Chen, JD; Fang, MS; Guo, XF; He, YQ; Jin, H; Li, LH; Liu, YJ; Shao, P; Wu, RR; Zhao, JP, 2008) |
| "Metformin (850-1700 mg) plus sibutramine (10-20 mg, n=13) or placebo (n=15) was administered for 12 weeks in olanzapine-treated chronic schizophrenia patients." | 9.13 | Metformin plus sibutramine for olanzapine-associated weight gain and metabolic dysfunction in schizophrenia: a 12-week double-blind, placebo-controlled pilot study. ( Baptista, T; Beaulieu, S; de Baptista, EA; El Fakih, Y; Galeazzi, T; Rangel, N; Uzcátegui, E, 2008) |
| "To evaluate the effect of metformin treatment on the risperidone-induced body weight gain in patients." | 9.13 | A randomized, double-blind, placebo-controlled trial of metformin treatment for weight gain associated with initiation of risperidone in children and adolescents. ( Arman, S; Koleini, N; Nadi, M; Sadramely, MR, 2008) |
| "The purpose of this study was to assess the efficacy of metformin in preventing olanzapine-induced weight gain." | 9.13 | Metformin addition attenuates olanzapine-induced weight gain in drug-naive first-episode schizophrenia patients: a double-blind, placebo-controlled study. ( Chen, JD; Fang, MS; Guo, WB; Guo, XF; He, YQ; Li, LH; Wu, RR; Zhao, JP, 2008) |
| " The primary objective of this study was to assess whether metformin prevents or reverses BWG in patients with schizophrenia or bipolar disorder under olanzapine administration." | 9.12 | Metformin as an adjunctive treatment to control body weight and metabolic dysfunction during olanzapine administration: a multicentric, double-blind, placebo-controlled trial. ( Baptista, T; Beaulieu, S; Carrizo, E; Connell, L; Dávila, A; de Baptista, EA; El Fakih, Y; Fernández, V; Galeazzi, T; Gutiérrez, MA; Rangel, N; Serrano, A; Servigna, M; Uzcátegui, E; Uzcátegui, M, 2007) |
| "To assess whether metformin prevents body weight gain (BWG) and metabolic dysfunction in patients with schizophrenia who are treated with olanzapine." | 9.12 | Metformin for prevention of weight gain and insulin resistance with olanzapine: a double-blind placebo-controlled trial. ( Arapé, Y; Baptista, T; Beaulieu, S; de Mendoza, S; Hernández, L; Lacruz, A; Martínez, J; Martinez, M; Rangel, N; Serrano, A; Teneud, L, 2006) |
| "Combining metformin and lifestyle intervention shows significant effect in reducing AP-related weight gain." | 9.01 | Combination of Metformin and Lifestyle Intervention for Antipsychotic-Related Weight Gain: A Meta-Analysis of Randomized Controlled Trials. ( Cai, DB; Ng, CH; Ungvari, GS; Wu, RR; Xiang, YT; Yang, XH; Zhang, QE; Zheng, W, 2019) |
| " This meta-analysis of randomized controlled trials systematically examined the efficacy and safety of adjunctive metformin for antipsychotic-related hyperprolactinemia in schizophrenia patients." | 8.95 | Adjunctive metformin for antipsychotic-related hyperprolactinemia: A meta-analysis of randomized controlled trials. ( Cai, DB; Ng, CH; Ning, YP; Ungvari, GS; Wang, N; Xiang, YT; Yang, XH; Zheng, W, 2017) |
| "All double blind placebo controlled trials assessing the efficacy of metformin in the treatment of antipsychotic induced weight gain were included." | 8.93 | Metformin in prevention and treatment of antipsychotic induced weight gain: a systematic review and meta-analysis. ( Dayabandara, M; de Silva, VA; Hanwella, R; Ratnatunga, SS; Suraweera, C; Wanniarachchi, N, 2016) |
| "We conducted a systematic-review and meta-analysis of metformin versus placebo for change in weight and metabolic syndrome for people on clozapine without diabetes mellitus." | 8.93 | Metformin for Clozapine Associated Obesity: A Systematic Review and Meta-Analysis. ( Kisely, S; Leung, J; Russell, AW; Siskind, DJ; Wysoczanski, D, 2016) |
| "Olanzapine is an atypical antipsychotic that is useful in schizophrenia and bipolar affective disorder, but its use is associated with troublesome weight gain and metabolic syndrome." | 8.87 | Metformin for olanzapine-induced weight gain: a systematic review and meta-analysis. ( Goyal, N; Jana, AK; Praharaj, SK; Sinha, VK, 2011) |
| "In this large retrospective naturalistic cohort study, co-prescription of clozapine and metformin was associated with less weight gain and related metabolic dysfunction at 6 and 12 months after initiation versus clozapine alone." | 8.12 | Metformin for the prevention of clozapine-induced weight gain: A retrospective naturalistic cohort study. ( Agarwal, SM; Chintoh, AF; Foussias, G; Gerretsen, P; Graff-Guerrero, A; Hahn, MK; Maksyutynska, K; Navagnanavel, J; Powell, V; Remington, G; Sanches, M; Stogios, N, 2022) |
| "Clozapine-induced prediabetes/diabetes occurred in 76." | 8.02 | Clozapine induces metformin-resistant prediabetes/diabetes that is associated with poor clinical efficacy in patients with early treatment-resistant schizophrenia. ( Chen, J; Chen, Y; Fang, T; Huang, G; Li, B; Li, Q; Lin, C; Liu, J; Ma, X; Shao, H; Tian, H; Wang, H; Xu, S; Xu, Y; Yang, A; Yang, W; Yao, C; Yu, X; Zhou, C; Zhuo, C, 2021) |
| " Because previous data suggest the procognitive potential of the antidiabetic drug metformin, this study aimed to assess the effects of chronic clozapine and metformin oral administration (alone and in combination) on locomotor and exploratory activities and cognitive function in a reward-based test in control and a schizophrenia-like animal model (Wisket rats)." | 8.02 | Interaction of clozapine with metformin in a schizophrenia rat model. ( Adlan, LG; Benyhe, S; Büki, A; Heni, HE; Horvath, G; Kekesi, G; Kis, G; Szűcs, E, 2021) |
| "Metformin attenuated the olanzapine- and risperidone-induced metabolic dysfunctions in MK801-induced schizophrenia-like rats without reducing the therapeutic effects of the antipsychotics." | 7.96 | Metformin attenuates antipsychotic-induced metabolic dysfunctions in MK801-induced schizophrenia-like rats. ( Huang, H; Li, X; Liu, Y; Liu, Z; Luo, C; Mao, X; Wang, X; Zhao, J; Zhou, H, 2020) |
| " Metformin, widely known as an antidiabetic drug, has been found to enhance spatial memory formation and improve anxiety-like behaviors in rodents." | 7.91 | Metformin reverses the schizophrenia-like behaviors induced by MK-801 in rats. ( Li, X; Liu, ZQ; Luo, C; Mao, XY; Wang, X; Yin, JY; Zhang, W; Zhou, HH, 2019) |
| "Metformin is effective in reducing weight in South Asian patients with schizophrenia or schizoaffective disorder who had increased their body by more than 10% after treatment with atypical antipsychotics." | 7.81 | Metformin for treatment of antipsychotic-induced weight gain in a South Asian population with schizophrenia or schizoaffective disorder: A double blind, randomized, placebo controlled study. ( Dayabandara, M; de Silva, VA; Gunewardena, H; Hanwella, R; Henegama, T; Suraweera, C; Wijesundara, H, 2015) |
| "Patients with schizophrenia have exceedingly high rates of metabolic comorbidity including type 2 diabetes and lose 15-20 years of life due to cardiovascular diseases, with early accrual of cardiometabolic disease." | 7.01 | Metformin for early comorbid glucose dysregulation and schizophrenia spectrum disorders: a pilot double-blind randomized clinical trial. ( Agarwal, SM; Caravaggio, F; Chintoh, AF; Costa-Dookhan, KA; Graff-Guerrero, A; Hahn, MK; Hashim, E; Kirpalani, A; Kramer, CK; Leung, G; MacKenzie, NE; Matheson, K; Panda, R; Remington, GJ; Treen, QC; Voineskos, AN, 2021) |
| "Clozapine, while effective in treatment refractory schizophrenia, is associated with significant weight gain, heart disease and increased risk of type 2 diabetes mellitus (T2DM)." | 5.27 | CoMET: a protocol for a randomised controlled trial of co-commencement of METformin as an adjunctive treatment to attenuate weight gain and metabolic syndrome in patients with schizophrenia newly commenced on clozapine. ( Baker, A; Flaws, D; Friend, N; Kisely, S; Lim, C; McGrath, JJ; Moudgil, V; Patterson, S; Russell, A; Sardinha, S; Siskind, D; Stedman, T; Suetani, S; Winckel, K, 2018) |
| "There is low-certainty evidence to suggest that metformin may be effective in preventing weight gain." | 5.22 | Pharmacological interventions for prevention of weight gain in people with schizophrenia. ( Agarwal, SM; Ahsan, ZA; Cohn, T; Duncan, MJ; Faulkner, GEJ; Hahn, M; Lockwood, JT; Remington, G; Stogios, N; Takeuchi, H; Taylor, VH, 2022) |
| "In this 12-week, randomized, double-blind, placebo-controlled trial, metformin at 500 mg/d or 1000 mg/d was prescribed to clozapine-treated patients with schizophrenia who had pre-existing metabolic abnormalities." | 5.22 | Effects of Low Dose Metformin on Metabolic Traits in Clozapine-Treated Schizophrenia Patients: An Exploratory Twelve-Week Randomized, Double-Blind, Placebo-Controlled Study. ( Chen, CH; Chen, PY; Chiu, CC; Huang, MC; Lin, SK; Lin, YK; Lu, ML, 2016) |
| " In this study, data were pooled from two randomized, placebo-controlled trials, which were originally designed to examine the efficacy of metformin in treating antipsychotic-induced weight gain and other metabolic abnormalities." | 5.22 | Metformin treatment of antipsychotic-induced dyslipidemia: an analysis of two randomized, placebo-controlled trials. ( Chan, PK; Gao, KM; Guo, WB; Jin, H; Ou, JJ; Shao, P; Wu, RR; Zhang, FY; Zhao, JP, 2016) |
| " We recruited patients with DSM-IV diagnosis of schizophrenia or schizoaffective disorder who had been taking clozapine for more than 3 months, were overweight or obese, or fulfilled at least 1 criteria of metabolic syndrome." | 5.17 | Effects of adjunctive metformin on metabolic traits in nondiabetic clozapine-treated patients with schizophrenia and the effect of metformin discontinuation on body weight: a 24-week, randomized, double-blind, placebo-controlled study. ( Chen, CH; Chiu, CC; Huang, MC; Kao, CF; Kuo, PH; Lin, SK; Lu, ML, 2013) |
| "Metformin was modestly effective in reducing weight and other risk factors for cardiovascular disease in clinically stable, overweight outpatients with chronic schizophrenia or schizoaffective disorder over 16 weeks." | 5.17 | Metformin for weight loss and metabolic control in overweight outpatients with schizophrenia and schizoaffective disorder. ( Catellier, DJ; Golden, LH; Hamer, RM; Jarskog, LF; Lavange, L; Lieberman, JA; Ray, N; Stewart, DD; Stroup, TS, 2013) |
| "Outpatients with schizophrenia or schizoaffective disorder (DSM-IV-TR criteria) were randomly assigned to olanzapine alone (n = 50), olanzapine plus algorithm A (olanzapine + A [amantadine 200 mg/d with possible switches to metformin 1,000-1,500 mg/d and then to zonisamide 100-400 mg/d; n = 76]), or olanzapine plus algorithm B (olanzapine + B [metformin 1,000-1,500 mg/d with possible switches to amantadine 200 mg/d and then to zonisamide 100-400 mg/d; n = 73])." | 5.16 | Assessment of treatment algorithms including amantadine, metformin, and zonisamide for the prevention of weight gain with olanzapine: a randomized controlled open-label study. ( Case, M; Hoffmann, VP; Jacobson, JG, 2012) |
| " The body weight, body mass index, fasting insulin and insulin resistance index decreased significantly in the metformin group, but increased in the placebo group during the 12-week follow-up period." | 5.16 | Metformin for treatment of antipsychotic-induced weight gain: a randomized, placebo-controlled study. ( Liang, GM; Tong, JH; Wang, M; Wang, XZ; Yan, HF; Zhu, G, 2012) |
| "Metformin was effective in reversing antipsychotic-induced adverse events, including restoration of menstruation, promotion of weight loss, and improvement in insulin resistance in female patients with schizophrenia." | 5.16 | Metformin for treatment of antipsychotic-induced amenorrhea and weight gain in women with first-episode schizophrenia: a double-blind, randomized, placebo-controlled study. ( Chan, PK; Davis, JM; Gao, K; Guo, XF; Jin, H; Ou, JJ; Shao, P; Twamley, EW; Wang, J; Wu, RR; Zhao, JP, 2012) |
| " Body mass index (BMI), waist circumference, serum glucose, HbA1C, lipids, leptin, cortisol, insulin resistance index (HOMA-IR), metabolic syndrome and the frequencies of SNPs were assessed in 56 CLZ-treated patients (78." | 5.14 | Polymorphisms of the LEP- and LEPR genes, metabolic profile after prolonged clozapine administration and response to the antidiabetic metformin. ( Baptista, T; Carrizo, E; Connell, L; de Baptista, EA; Fernández, E; Fernández, I; Fernández, V; Mogollón, J; Prieto, D; Sandia, I; Valbuena, D, 2010) |
| "Clozapine is the most effective agent in treatment-resistant schizophrenia." | 5.14 | Extended release metformin for metabolic control assistance during prolonged clozapine administration: a 14 week, double-blind, parallel group, placebo-controlled study. ( Baptista, T; Carrizo, E; Connell, L; de Baptista, EA; Fernández, I; Fernández, V; Mogollón, J; Prieto, D; Sandia, I; Valbuena, D, 2009) |
| "To evaluate the effect of metformin treatment on the risperidone-induced body weight gain in patients." | 5.13 | A randomized, double-blind, placebo-controlled trial of metformin treatment for weight gain associated with initiation of risperidone in children and adolescents. ( Arman, S; Koleini, N; Nadi, M; Sadramely, MR, 2008) |
| "The second generation antipsychotic drugs, such as risperidone, olanzapine, and quetiapine, are effective in treating patients with schizophrenia and have been considered as the first line therapy." | 5.13 | Metformin for metabolic dysregulation in schizophrenic patients treated with olanzapine. ( Chen, CH; Chiu, CC; Huang, MC; Liu, HC; Lu, ML; Wu, TH, 2008) |
| "Lifestyle intervention and metformin alone and in combination demonstrated efficacy for antipsychotic-induced weight gain." | 5.13 | Lifestyle intervention and metformin for treatment of antipsychotic-induced weight gain: a randomized controlled trial. ( Chen, JD; Fang, MS; Guo, XF; He, YQ; Jin, H; Li, LH; Liu, YJ; Shao, P; Wu, RR; Zhao, JP, 2008) |
| "The purpose of this study was to assess the efficacy of metformin in preventing olanzapine-induced weight gain." | 5.13 | Metformin addition attenuates olanzapine-induced weight gain in drug-naive first-episode schizophrenia patients: a double-blind, placebo-controlled study. ( Chen, JD; Fang, MS; Guo, WB; Guo, XF; He, YQ; Li, LH; Wu, RR; Zhao, JP, 2008) |
| "Metformin (850-1700 mg) plus sibutramine (10-20 mg, n=13) or placebo (n=15) was administered for 12 weeks in olanzapine-treated chronic schizophrenia patients." | 5.13 | Metformin plus sibutramine for olanzapine-associated weight gain and metabolic dysfunction in schizophrenia: a 12-week double-blind, placebo-controlled pilot study. ( Baptista, T; Beaulieu, S; de Baptista, EA; El Fakih, Y; Galeazzi, T; Rangel, N; Uzcátegui, E, 2008) |
| "To assess whether metformin prevents body weight gain (BWG) and metabolic dysfunction in patients with schizophrenia who are treated with olanzapine." | 5.12 | Metformin for prevention of weight gain and insulin resistance with olanzapine: a double-blind placebo-controlled trial. ( Arapé, Y; Baptista, T; Beaulieu, S; de Mendoza, S; Hernández, L; Lacruz, A; Martínez, J; Martinez, M; Rangel, N; Serrano, A; Teneud, L, 2006) |
| "In this study, the Authors assessed some insulin counter-regulatory factors, fibrinogen and C-reactive protein after olanzapine administration, and the effect of metformin on these variables, 37 patients with chronic schizophrenia were given olanzapine (10 mg/day for 14 weeks)." | 5.12 | Insulin counter-regulatory factors, fibrinogen and C-reactive protein during olanzapine administration: effects of the antidiabetic metformin. ( Baptista, T; Beaulieu, S; Contreras, Q; de Mendoza, S; Galeazzi, T; Lacruz, A; Rangel, N; Sandia, I; Vargas, D, 2007) |
| " The primary objective of this study was to assess whether metformin prevents or reverses BWG in patients with schizophrenia or bipolar disorder under olanzapine administration." | 5.12 | Metformin as an adjunctive treatment to control body weight and metabolic dysfunction during olanzapine administration: a multicentric, double-blind, placebo-controlled trial. ( Baptista, T; Beaulieu, S; Carrizo, E; Connell, L; Dávila, A; de Baptista, EA; El Fakih, Y; Fernández, V; Galeazzi, T; Gutiérrez, MA; Rangel, N; Serrano, A; Servigna, M; Uzcátegui, E; Uzcátegui, M, 2007) |
| "Combining metformin and lifestyle intervention shows significant effect in reducing AP-related weight gain." | 5.01 | Combination of Metformin and Lifestyle Intervention for Antipsychotic-Related Weight Gain: A Meta-Analysis of Randomized Controlled Trials. ( Cai, DB; Ng, CH; Ungvari, GS; Wu, RR; Xiang, YT; Yang, XH; Zhang, QE; Zheng, W, 2019) |
| " This meta-analysis of randomized controlled trials systematically examined the efficacy and safety of adjunctive metformin for antipsychotic-related hyperprolactinemia in schizophrenia patients." | 4.95 | Adjunctive metformin for antipsychotic-related hyperprolactinemia: A meta-analysis of randomized controlled trials. ( Cai, DB; Ng, CH; Ning, YP; Ungvari, GS; Wang, N; Xiang, YT; Yang, XH; Zheng, W, 2017) |
| "All double blind placebo controlled trials assessing the efficacy of metformin in the treatment of antipsychotic induced weight gain were included." | 4.93 | Metformin in prevention and treatment of antipsychotic induced weight gain: a systematic review and meta-analysis. ( Dayabandara, M; de Silva, VA; Hanwella, R; Ratnatunga, SS; Suraweera, C; Wanniarachchi, N, 2016) |
| "We conducted a systematic-review and meta-analysis of metformin versus placebo for change in weight and metabolic syndrome for people on clozapine without diabetes mellitus." | 4.93 | Metformin for Clozapine Associated Obesity: A Systematic Review and Meta-Analysis. ( Kisely, S; Leung, J; Russell, AW; Siskind, DJ; Wysoczanski, D, 2016) |
| "Olanzapine is an atypical antipsychotic that is useful in schizophrenia and bipolar affective disorder, but its use is associated with troublesome weight gain and metabolic syndrome." | 4.87 | Metformin for olanzapine-induced weight gain: a systematic review and meta-analysis. ( Goyal, N; Jana, AK; Praharaj, SK; Sinha, VK, 2011) |
| " Metformin has attracted attention as a potential treatment option because it is thought to result in weight reduction and improved glycemic control in obese patients with and without type 2 diabetes mellitus." | 4.86 | The adjunctive use of metformin to treat or prevent atypical antipsychotic-induced weight gain: a review. ( Ali, F; Dahmen, MM; Girrens, K; Khan, AY; Macaluso, M; McHale, RJ, 2010) |
| "In this large retrospective naturalistic cohort study, co-prescription of clozapine and metformin was associated with less weight gain and related metabolic dysfunction at 6 and 12 months after initiation versus clozapine alone." | 4.12 | Metformin for the prevention of clozapine-induced weight gain: A retrospective naturalistic cohort study. ( Agarwal, SM; Chintoh, AF; Foussias, G; Gerretsen, P; Graff-Guerrero, A; Hahn, MK; Maksyutynska, K; Navagnanavel, J; Powell, V; Remington, G; Sanches, M; Stogios, N, 2022) |
| " Because previous data suggest the procognitive potential of the antidiabetic drug metformin, this study aimed to assess the effects of chronic clozapine and metformin oral administration (alone and in combination) on locomotor and exploratory activities and cognitive function in a reward-based test in control and a schizophrenia-like animal model (Wisket rats)." | 4.02 | Interaction of clozapine with metformin in a schizophrenia rat model. ( Adlan, LG; Benyhe, S; Büki, A; Heni, HE; Horvath, G; Kekesi, G; Kis, G; Szűcs, E, 2021) |
| "This study shows PCOS patients are at increased risk of incident schizophrenia, and the metformin treatment has a protective effect against incident schizophrenia." | 4.02 | Risk of schizophrenia in patients with polycystic ovary syndrome: a nationwide population-based cohort study from Taiwan. ( Chen, SF; Hsu, CY; Shen, YC; Yang, YC, 2021) |
| "Clozapine-induced prediabetes/diabetes occurred in 76." | 4.02 | Clozapine induces metformin-resistant prediabetes/diabetes that is associated with poor clinical efficacy in patients with early treatment-resistant schizophrenia. ( Chen, J; Chen, Y; Fang, T; Huang, G; Li, B; Li, Q; Lin, C; Liu, J; Ma, X; Shao, H; Tian, H; Wang, H; Xu, S; Xu, Y; Yang, A; Yang, W; Yao, C; Yu, X; Zhou, C; Zhuo, C, 2021) |
| "Metformin attenuated the olanzapine- and risperidone-induced metabolic dysfunctions in MK801-induced schizophrenia-like rats without reducing the therapeutic effects of the antipsychotics." | 3.96 | Metformin attenuates antipsychotic-induced metabolic dysfunctions in MK801-induced schizophrenia-like rats. ( Huang, H; Li, X; Liu, Y; Liu, Z; Luo, C; Mao, X; Wang, X; Zhao, J; Zhou, H, 2020) |
| " Metformin, widely known as an antidiabetic drug, has been found to enhance spatial memory formation and improve anxiety-like behaviors in rodents." | 3.91 | Metformin reverses the schizophrenia-like behaviors induced by MK-801 in rats. ( Li, X; Liu, ZQ; Luo, C; Mao, XY; Wang, X; Yin, JY; Zhang, W; Zhou, HH, 2019) |
| "Metformin is effective in reducing weight in South Asian patients with schizophrenia or schizoaffective disorder who had increased their body by more than 10% after treatment with atypical antipsychotics." | 3.81 | Metformin for treatment of antipsychotic-induced weight gain in a South Asian population with schizophrenia or schizoaffective disorder: A double blind, randomized, placebo controlled study. ( Dayabandara, M; de Silva, VA; Gunewardena, H; Hanwella, R; Henegama, T; Suraweera, C; Wijesundara, H, 2015) |
| " At the beginning of the therapy, among the biochemical measurements, insulin resistance was defined and metformin treatment was begun." | 3.74 | Nutritional approach to metabolic changes arising out of schizophrenia therapy: case report. ( Balci, H; Eker, E; Ozenoglu, A; Ugurlu, S, 2007) |
| "Patients with schizophrenia have exceedingly high rates of metabolic comorbidity including type 2 diabetes and lose 15-20 years of life due to cardiovascular diseases, with early accrual of cardiometabolic disease." | 3.01 | Metformin for early comorbid glucose dysregulation and schizophrenia spectrum disorders: a pilot double-blind randomized clinical trial. ( Agarwal, SM; Caravaggio, F; Chintoh, AF; Costa-Dookhan, KA; Graff-Guerrero, A; Hahn, MK; Hashim, E; Kirpalani, A; Kramer, CK; Leung, G; MacKenzie, NE; Matheson, K; Panda, R; Remington, GJ; Treen, QC; Voineskos, AN, 2021) |
| "The prevalence of type 2 diabetes is increased in individuals with mental disorders." | 2.72 | Interventions for preventing type 2 diabetes in adults with mental disorders in low- and middle-income countries. ( Ajjan, RA; Al Azdi, Z; Aslam, F; Churchill, R; Mishu, MP; Philip, S; Siddiqi, N; Stubbs, B; Tirbhowan, N; Uphoff, E; Wright, J, 2021) |
| "Patients with schizophrenia have increased prevalence rates for many cardiometabolic risk factors; the prevalence and severity of these risks increase after the institution of antipsychotic medication." | 2.53 | Cardiometabolic Risks in Schizophrenia and Directions for Intervention, 3: Psychopharmacological Interventions. ( Andrade, C, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (1.79) | 18.2507 |
| 2000's | 16 (28.57) | 29.6817 |
| 2010's | 31 (55.36) | 24.3611 |
| 2020's | 8 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Zhuo, C | 1 |
| Xu, Y | 1 |
| Wang, H | 1 |
| Zhou, C | 1 |
| Liu, J | 1 |
| Yu, X | 1 |
| Shao, H | 1 |
| Tian, H | 1 |
| Fang, T | 1 |
| Li, Q | 1 |
| Chen, J | 1 |
| Xu, S | 1 |
| Ma, X | 1 |
| Yang, W | 1 |
| Yao, C | 1 |
| Li, B | 1 |
| Yang, A | 1 |
| Chen, Y | 1 |
| Huang, G | 1 |
| Lin, C | 1 |
| Stogios, N | 2 |
| Maksyutynska, K | 1 |
| Navagnanavel, J | 1 |
| Sanches, M | 1 |
| Powell, V | 1 |
| Gerretsen, P | 1 |
| Graff-Guerrero, A | 2 |
| Chintoh, AF | 2 |
| Foussias, G | 1 |
| Remington, G | 2 |
| Hahn, MK | 2 |
| Agarwal, SM | 3 |
| Ahsan, ZA | 1 |
| Lockwood, JT | 1 |
| Duncan, MJ | 1 |
| Takeuchi, H | 1 |
| Cohn, T | 1 |
| Taylor, VH | 1 |
| Faulkner, GEJ | 1 |
| Hahn, M | 1 |
| Chen, SF | 1 |
| Yang, YC | 1 |
| Hsu, CY | 1 |
| Shen, YC | 1 |
| Luo, C | 2 |
| Wang, X | 2 |
| Mao, X | 1 |
| Huang, H | 1 |
| Liu, Y | 1 |
| Zhao, J | 1 |
| Zhou, H | 1 |
| Liu, Z | 1 |
| Li, X | 2 |
| Mishu, MP | 1 |
| Uphoff, E | 1 |
| Aslam, F | 1 |
| Philip, S | 1 |
| Wright, J | 1 |
| Tirbhowan, N | 1 |
| Ajjan, RA | 1 |
| Al Azdi, Z | 1 |
| Stubbs, B | 1 |
| Churchill, R | 1 |
| Siddiqi, N | 1 |
| Panda, R | 1 |
| Costa-Dookhan, KA | 1 |
| MacKenzie, NE | 1 |
| Treen, QC | 1 |
| Caravaggio, F | 1 |
| Hashim, E | 1 |
| Leung, G | 1 |
| Kirpalani, A | 1 |
| Matheson, K | 1 |
| Kramer, CK | 1 |
| Voineskos, AN | 1 |
| Remington, GJ | 1 |
| Horvath, G | 1 |
| Kis, G | 1 |
| Kekesi, G | 1 |
| Büki, A | 1 |
| Adlan, LG | 1 |
| Szűcs, E | 1 |
| Heni, HE | 1 |
| Benyhe, S | 1 |
| Pinto, EF | 1 |
| George, B | 1 |
| Karia, S | 1 |
| Andrade, C | 2 |
| Zheng, W | 2 |
| Yang, XH | 2 |
| Cai, DB | 2 |
| Ungvari, GS | 2 |
| Ng, CH | 2 |
| Wang, N | 1 |
| Ning, YP | 1 |
| Xiang, YT | 2 |
| Zhang, QE | 1 |
| Wu, RR | 5 |
| Siskind, D | 1 |
| Friend, N | 1 |
| Russell, A | 1 |
| McGrath, JJ | 1 |
| Lim, C | 1 |
| Patterson, S | 1 |
| Flaws, D | 1 |
| Stedman, T | 1 |
| Moudgil, V | 1 |
| Sardinha, S | 1 |
| Suetani, S | 1 |
| Kisely, S | 2 |
| Winckel, K | 1 |
| Baker, A | 1 |
| Mao, XY | 1 |
| Yin, JY | 1 |
| Zhang, W | 1 |
| Zhou, HH | 1 |
| Liu, ZQ | 1 |
| Chen, CH | 4 |
| Huang, MC | 4 |
| Kao, CF | 2 |
| Lin, SK | 3 |
| Kuo, PH | 2 |
| Chiu, CC | 4 |
| Lu, ML | 4 |
| Jarskog, LF | 2 |
| Hamer, RM | 1 |
| Catellier, DJ | 1 |
| Stewart, DD | 1 |
| Lavange, L | 1 |
| Ray, N | 1 |
| Golden, LH | 1 |
| Lieberman, JA | 1 |
| Stroup, TS | 2 |
| Correll, CU | 1 |
| Sikich, L | 1 |
| Reeves, G | 1 |
| Riddle, M | 1 |
| Rosenfeld, JE | 1 |
| Tek, C | 1 |
| Chwastiak, L | 1 |
| McGinty, EE | 1 |
| Baller, J | 1 |
| Azrin, ST | 1 |
| Juliano-Bult, D | 1 |
| Daumit, GL | 1 |
| Chen, PY | 2 |
| de Silva, VA | 2 |
| Dayabandara, M | 2 |
| Wijesundara, H | 1 |
| Henegama, T | 1 |
| Gunewardena, H | 1 |
| Suraweera, C | 2 |
| Hanwella, R | 2 |
| Zhang, FY | 1 |
| Gao, KM | 1 |
| Ou, JJ | 2 |
| Shao, P | 3 |
| Jin, H | 3 |
| Guo, WB | 2 |
| Chan, PK | 2 |
| Zhao, JP | 4 |
| McFadden, M | 1 |
| Gordon, A | 1 |
| Leong, G | 1 |
| Ward, D | 1 |
| Scott, JG | 1 |
| Chen, WH | 1 |
| Huang, WL | 1 |
| Hsieh, MH | 1 |
| Siskind, DJ | 1 |
| Leung, J | 1 |
| Russell, AW | 1 |
| Wysoczanski, D | 1 |
| Ratnatunga, SS | 1 |
| Wanniarachchi, N | 1 |
| Lin, YK | 1 |
| Arman, S | 1 |
| Sadramely, MR | 1 |
| Nadi, M | 1 |
| Koleini, N | 1 |
| Alamiri, B | 1 |
| Balf, G | 1 |
| Carrizo, E | 3 |
| Fernández, V | 3 |
| Connell, L | 3 |
| Sandia, I | 3 |
| Prieto, D | 2 |
| Mogollón, J | 2 |
| Valbuena, D | 2 |
| Fernández, I | 2 |
| de Baptista, EA | 4 |
| Baptista, T | 7 |
| Housel, AK | 1 |
| Waterbury, N | 1 |
| Argo, TR | 1 |
| Winsberg, B | 2 |
| Yeager, C | 1 |
| Hobbs, B | 2 |
| Wei, R | 1 |
| Elangovan, N | 1 |
| Fernández, E | 1 |
| Khan, AY | 1 |
| Macaluso, M | 1 |
| McHale, RJ | 1 |
| Dahmen, MM | 1 |
| Girrens, K | 1 |
| Ali, F | 1 |
| Hasnain, M | 1 |
| Fredrickson, SK | 1 |
| Vieweg, WV | 1 |
| Praharaj, SK | 1 |
| Jana, AK | 1 |
| Goyal, N | 1 |
| Sinha, VK | 1 |
| Hoffmann, VP | 1 |
| Case, M | 1 |
| Jacobson, JG | 1 |
| Yeager, CA | 1 |
| Wang, M | 1 |
| Tong, JH | 1 |
| Zhu, G | 1 |
| Liang, GM | 1 |
| Yan, HF | 1 |
| Wang, XZ | 1 |
| Gao, K | 1 |
| Twamley, EW | 1 |
| Wang, J | 1 |
| Guo, XF | 3 |
| Davis, JM | 1 |
| Smith, RC | 1 |
| Dibben, CR | 1 |
| Kalavalapalli, SS | 1 |
| Linnington, HE | 1 |
| Hynes, FA | 1 |
| Dinneen, SF | 1 |
| Adler, AI | 1 |
| McKenna, PJ | 1 |
| Martínez, J | 1 |
| Lacruz, A | 2 |
| Rangel, N | 4 |
| Beaulieu, S | 4 |
| Serrano, A | 2 |
| Arapé, Y | 1 |
| Martinez, M | 1 |
| de Mendoza, S | 3 |
| Teneud, L | 1 |
| Hernández, L | 2 |
| Contreras, Q | 1 |
| Galeazzi, T | 3 |
| Vargas, D | 1 |
| El Fakih, Y | 2 |
| Uzcátegui, E | 2 |
| Gutiérrez, MA | 1 |
| Servigna, M | 1 |
| Dávila, A | 1 |
| Uzcátegui, M | 1 |
| Ozenoglu, A | 1 |
| Ugurlu, S | 1 |
| Balci, H | 1 |
| Eker, E | 1 |
| Wu, TH | 1 |
| Liu, HC | 1 |
| Fang, MS | 2 |
| He, YQ | 2 |
| Liu, YJ | 1 |
| Chen, JD | 2 |
| Li, LH | 2 |
| Venkatasubramanian, G | 1 |
| McDonnell, ME | 1 |
| Ruderman, NB | 1 |
| Prieto, LA | 1 |
| Boyero, EC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Comparison of Bupropion SR and Placebo for Smoking Cessation[NCT00176449] | Phase 4 | 52 participants (Actual) | Interventional | 2001-04-30 | Completed | ||
| Metformin in Co-morbid Diabetes or Prediabetes and Serious Mental Illness[NCT02167620] | Phase 4 | 35 participants (Actual) | Interventional | 2014-06-30 | Completed | ||
| Prevalence of Metabolic Syndrome and Effects of Adjunctive Metformin on Metabolic Profiles in Clozapine-treated Schizophrenic Patients[NCT01300637] | 60 participants (Anticipated) | Interventional | 2008-11-30 | Recruiting | |||
| Metformin in the Treatment of Antipsychotic-Induced Weight Gain in Schizophrenia (METS) - Pilot Study[NCT00816907] | Phase 4 | 146 participants (Actual) | Interventional | 2009-01-31 | Completed | ||
| Metformin and Lorcaserin for Weight Loss in Schizophrenia[NCT02796144] | Phase 4 | 71 participants (Actual) | Interventional | 2016-09-30 | Terminated (stopped due to The FDA advised of a possible health risk associated with lorcaserin and the drug is being withdrawn.) | ||
| Efficacy and Safety of Add-on Topiramate vs Metformin on Cardio-Metabolic Profile in Patients With Schizophrenia on Atypical Antipsychotics With Metabolic Syndrome: a Randomized Controlled Trial[NCT05663749] | Phase 4 | 60 participants (Actual) | Interventional | 2022-09-20 | Completed | ||
| Open-label, Flexible-dose Adjunctive Bromocriptine for Patients With Schizophrenia and Impaired Glucose Tolerance[NCT03575000] | Phase 4 | 20 participants (Anticipated) | Interventional | 2023-11-01 | Not yet recruiting | ||
| Treatment of Metabolic Abnormalities in Patients With Schizophrenia: Adjunctive Low-dose Metformin in Patients With Schizophrenia and Metabolic Abnormalities[NCT02751307] | Phase 4 | 55 participants (Actual) | Interventional | 2013-05-31 | Completed | ||
| Use of Metformin in Prevention and Treatment of Cardiac Fibrosis in PAI-1 Deficient Population[NCT05317806] | Phase 4 | 15 participants (Anticipated) | Interventional | 2022-10-10 | Active, not recruiting | ||
| The Assessment of the Safety, Efficacy, and Practicality of an Algorithm Including Amantadine, Metformin and Zonisamide for the Prevention of Olanzapine-Associated Weight Gain in Outpatients With Schizophrenia[NCT00401973] | Phase 3 | 199 participants (Actual) | Interventional | 2006-11-30 | Completed | ||
| Efficacy of Lifestyle Interventions and Metformin for the Treatment of Antipsychotic-Induced Weight Gain: a Randomized Double-Blind Placebo- Controlled Comparison[NCT00451399] | Phase 4 | 128 participants | Interventional | 2004-10-31 | Completed | ||
| Efficacy and Safety of Metformin in Preventing Patients With Risperidone From Weight Gain and Amenorrhea:a 24-week, Randomized, Placebo-controlled, Double-blind, Fixed-dose Study[NCT01423487] | 0 participants (Actual) | Interventional | 2011-08-31 | Withdrawn (stopped due to Difficult to obtain informed consent) | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
fasting blood glucose (NCT00816907)
Timeframe: 16 weeks
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Placebo | -1.6 |
| Metformin | -2.3 |
Fasting insulin (NCT00816907)
Timeframe: 16 weeks
| Intervention | mU/L (Mean) |
|---|---|
| Placebo | 5.5 |
| Metformin | 1.6 |
high-density lipoprotein (NCT00816907)
Timeframe: 16 weeks
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Placebo | -0.4 |
| Metformin | -0.6 |
glycosylated hemoglobin (NCT00816907)
Timeframe: 16 weeks
| Intervention | percent (Least Squares Mean) |
|---|---|
| Placebo | 0.01 |
| Metformin | -0.06 |
low-density lipoprotein (NCT00816907)
Timeframe: 16 weeks
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Placebo | -2.0 |
| Metformin | -7.1 |
Total cholesterol (NCT00816907)
Timeframe: 16 weeks
| Intervention | mg/dL (Mean) |
|---|---|
| Placebo | 0.2 |
| Metformin | -8.9 |
serum triglycerides (NCT00816907)
Timeframe: 16 weeks
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Placebo | 13.2 |
| Metformin | -7.0 |
Mean difference in body weight change between participants assigned to metformin and participants assigned to placebo from baseline to last study visit (up to 16 weeks) (NCT00816907)
Timeframe: Measured at the last study visit
| Intervention | kilograms (Mean) |
|---|---|
| Placebo | -1.0 |
| Metformin | -3.0 |
Change in body weight in participants assigned to lorcaserin monotherapy treatment and participants assigned to placebo from baseline to last study visit (up to 52 weeks) (NCT02796144)
Timeframe: Baseline, Last Observed Visit (Up to 52 weeks)
| Intervention | pounds (Mean) |
|---|---|
| Lorcaserin | -5.18 |
| Placebo | -3.02 |
Change in body weight in participants assigned to lorcaserin/metformin combination treatment and participants assigned to placebo from baseline to last study visit (up to 52 weeks) (NCT02796144)
Timeframe: Baseline, Last Observed Visit (Up to 52 weeks)
| Intervention | pounds (Mean) |
|---|---|
| Lorcaserin and Metformin | -13.05 |
| Placebo | -3.02 |
fasting blood glucose (NCT02796144)
Timeframe: Baseline, Last Observed Visit (Up to 52 weeks)
| Intervention | mg/dL (Mean) |
|---|---|
| Lorcaserin and Metformin | -4.30 |
| Lorcaserin | -3.27 |
| Placebo | 3.53 |
high-density lipoprotein (NCT02796144)
Timeframe: Baseline, Last Observed Visit (Up to 52 weeks)
| Intervention | mg/dL (Mean) |
|---|---|
| Lorcaserin and Metformin | 3.8 |
| Lorcaserin | 1.45 |
| Placebo | -0.78 |
glycosylated hemoglobin (NCT02796144)
Timeframe: Baseline, Last Observed Visit (Up to 52 weeks)
| Intervention | percentage of glycosylated hemoglobin (Mean) |
|---|---|
| Lorcaserin and Metformin | -0.03 |
| Lorcaserin | 0.07 |
| Placebo | 0.05 |
low-density lipoprotein (NCT02796144)
Timeframe: Baseline, Last Observed Visit (Up to 52 weeks)
| Intervention | mg/dL (Mean) |
|---|---|
| Lorcaserin and Metformin | -7.60 |
| Lorcaserin | -10.86 |
| Placebo | -6.83 |
Total Cholesterol (NCT02796144)
Timeframe: Baseline, Last Observed Visit (Up to 52 weeks)
| Intervention | mg/dL (Mean) |
|---|---|
| Lorcaserin and Metformin | -9.05 |
| Lorcaserin | -13.45 |
| Placebo | -9.21 |
serum triglycerides (NCT02796144)
Timeframe: Baseline, Last Observed Visit (Up to 52 weeks)
| Intervention | mg/dL (Mean) |
|---|---|
| Lorcaserin and Metformin | -18.60 |
| Lorcaserin | -19.68 |
| Placebo | -3.11 |
(NCT00401973)
Timeframe: Baseline to endpoint (22 weeks)
| Intervention | kilograms (Least Squares Mean) |
|---|---|
| Olanzapine | 2.76 |
| Olanzapine + Amantadine | 2.40 |
| Olanzapine + Metformin | 0.65 |
The BPRS is an 18-item clinician-administered scale used to assess the degree of severity of a subject's general psychopathological symptoms. Each item is rated on a scale from 1 (symptom not present) to 7 (symptom extremely severe). The BPRS total score ranges from 18 to 126. (NCT00401973)
Timeframe: Baseline to endpoint (22 weeks)
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline | Change from Baseline | |
| Olanzapine | 48.24 | -13.89 |
| Olanzapine + Amantadine | 45.90 | -9.90 |
| Olanzapine + Metformin | 47.00 | -9.72 |
Measures severity of illness at the time of assessment compared with start of treatment. Scores range from 1 (normal, not at all ill) to 7 (among the most extremely ill patients). (NCT00401973)
Timeframe: Baseline to endpoint (22 weeks)
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline | Change from Baseline | |
| Olanzapine | 4.06 | -0.98 |
| Olanzapine + Amantadine | 4.03 | -0.72 |
| Olanzapine + Metformin | 4.00 | -0.79 |
The MADRS is a rating scale for severity of depressive mood symptoms. The MADRS has a 10-item checklist. Items are rated on a scale of 0-6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms). (NCT00401973)
Timeframe: Baseline to endpoint (22 weeks)
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline | Change from Baseline | |
| Olanzapine | 12.76 | -6.39 |
| Olanzapine + Amantadine | 14.22 | -4.12 |
| Olanzapine + Metformin | 15.40 | -4.36 |
To understand the drivers of weight gain as indicated by the correlation between weight changes and changes in the Eating Inventory (EI) and Food Craving Inventory (FCI). The EI is a 51-item inventory that measures dietary restraint, disinhibition, and perceived hunger. The FCI is a 28-item instrument measuring the frequency over the past month of general cravings and cravings for specific types of foods, namely: high fats, sweets, carbohydrates/starches, and fast-food fats. Correlations were computed on the combined treatment groups. (NCT00401973)
Timeframe: Baseline to endpoint (22 weeks)
| Intervention | correlation (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| EI: Disinhibition | EI: Cognitive Restraint | EI: Hunger | FCI: Carbohydrates/Starches (N=186, N=141) | FCI: Fast Food Fats (N=188, N=140) | FCI: High Fats (N=186, N=138) | FCI: Sweets (N=187, N=140) | FCI: Total Score (N=184, N=137) | |
| 2 Weeks | -0.034 | -0.273 | -0.150 | 0.013 | -0.019 | 0.051 | 0.022 | 0.039 |
| 22 Weeks | 0.285 | -0.038 | 0.148 | -0.064 | 0.047 | 0.043 | -0.008 | -0.000 |
(NCT00401973)
Timeframe: Baseline to endpoint (22 weeks)
| Intervention | millimole per Liter (mmol/L) (Mean) | |
|---|---|---|
| Baseline | Change from Baseline | |
| Olanzapine | 5.32 | 0.26 |
| Olanzapine + Amantadine | 5.25 | 0.10 |
| Olanzapine + Metformin | 5.28 | 0.01 |
(NCT00401973)
Timeframe: Baseline to endpoint (22 weeks)
| Intervention | millimole per liter (mmol/L) (Mean) | |
|---|---|---|
| Baseline | Change from Baseline | |
| Olanzapine | 1.25 | -0.00 |
| Olanzapine + Amantadine | 1.26 | -0.11 |
| Olanzapine + Metformin | 1.22 | -0.08 |
(NCT00401973)
Timeframe: Baseline to endpoint (22 weeks)
| Intervention | millimole per Liter (mmol/L) (Mean) | |
|---|---|---|
| Baseline | Change from Baseline | |
| Olanzapine | 3.02 | 0.16 |
| Olanzapine + Amantadine | 3.06 | -0.04 |
| Olanzapine + Metformin | 2.91 | -0.02 |
(NCT00401973)
Timeframe: Baseline to endpoint (22 weeks)
| Intervention | millimole per Liter (mmol/L) (Mean) | |
|---|---|---|
| Baseline | Change from Baseline | |
| Olanzapine | 5.01 | 0.36 |
| Olanzapine + Amantadine | 5.03 | 0.01 |
| Olanzapine + Metformin | 4.91 | -0.08 |
(NCT00401973)
Timeframe: Baseline to endpoint (22 weeks)
| Intervention | millimoles per Liter (mmol/L) (Mean) | |
|---|---|---|
| Baseline | Change from Baseline | |
| Olanzapine | 1.58 | 0.33 |
| Olanzapine + Amantadine | 1.61 | 0.35 |
| Olanzapine + Metformin | 1.68 | 0.06 |
(NCT00401973)
Timeframe: Baseline to endpoint (22 weeks)
| Intervention | percent hemoglobin A1c (Mean) | |
|---|---|---|
| Baseline | Change from Baseline | |
| Olanzapine | 5.51 | 0.09 |
| Olanzapine + Amantadine | 5.48 | 0.10 |
| Olanzapine + Metformin | 5.53 | -0.03 |
12 reviews available for metformin and Schizophrenia
| Article | Year |
|---|---|
Pharmacological interventions for prevention of weight gain in people with schizophrenia.
Topics: Antipsychotic Agents; Betahistine; Famotidine; Fluoxetine; Humans; Melatonin; Metformin; Nausea; Niz | 2022 |
Interventions for preventing type 2 diabetes in adults with mental disorders in low- and middle-income countries.
Topics: Adult; Aged; Antidepressive Agents, Tricyclic; Antioxidants; Antipsychotic Agents; Blood Glucose; Bo | 2021 |
Adjunctive metformin for antipsychotic-related hyperprolactinemia: A meta-analysis of randomized controlled trials.
Topics: Adolescent; Adult; Antipsychotic Agents; Female; Humans; Hyperprolactinemia; Male; Metformin; Middle | 2017 |
Combination of Metformin and Lifestyle Intervention for Antipsychotic-Related Weight Gain: A Meta-Analysis of Randomized Controlled Trials.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Combined Modality Therapy; Drug-Related Side Effects | 2019 |
Interventions to Address Medical Conditions and Health-Risk Behaviors Among Persons With Serious Mental Illness: A Comprehensive Review.
Topics: Behavior Therapy; Bipolar Disorder; Bupropion; Cardiovascular Diseases; Diabetes Mellitus; Dopamine | 2016 |
Metformin for Clozapine Associated Obesity: A Systematic Review and Meta-Analysis.
Topics: Antipsychotic Agents; Blood Glucose; Body Mass Index; Body Weight; Clozapine; Fasting; Humans; Hypog | 2016 |
Metformin in prevention and treatment of antipsychotic induced weight gain: a systematic review and meta-analysis.
Topics: Antipsychotic Agents; Double-Blind Method; Humans; Metformin; Psychotic Disorders; Schizophrenia; We | 2016 |
Cardiometabolic Risks in Schizophrenia and Directions for Intervention, 3: Psychopharmacological Interventions.
Topics: Anti-Obesity Agents; Antipsychotic Agents; Aripiprazole; Cardiovascular Diseases; Fructose; Humans; | 2016 |
Can metformin or rosiglitazone reduce metabolic side effects associated with atypical antipsychotics?
Topics: Antipsychotic Agents; Humans; Hypoglycemic Agents; Metabolic Syndrome; Metformin; Randomized Control | 2009 |
The adjunctive use of metformin to treat or prevent atypical antipsychotic-induced weight gain: a review.
Topics: Antipsychotic Agents; Blood Glucose; Body Weight; Humans; Hypoglycemic Agents; Metformin; Obesity; O | 2010 |
Metformin for obesity and glucose dysregulation in patients with schizophrenia receiving antipsychotic drugs.
Topics: Antipsychotic Agents; Cardiovascular Diseases; Glucose Metabolism Disorders; Humans; Hypoglycemic Ag | 2011 |
Metformin for olanzapine-induced weight gain: a systematic review and meta-analysis.
Topics: Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Blood Glucose; Body Mass Index; Humans; Hyp | 2011 |
21 trials available for metformin and Schizophrenia
| Article | Year |
|---|---|
Metformin for early comorbid glucose dysregulation and schizophrenia spectrum disorders: a pilot double-blind randomized clinical trial.
Topics: Adult; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Glucose; Humans; Hypoglycemic | 2021 |
CoMET: a protocol for a randomised controlled trial of co-commencement of METformin as an adjunctive treatment to attenuate weight gain and metabolic syndrome in patients with schizophrenia newly commenced on clozapine.
Topics: Antipsychotic Agents; Body Mass Index; Body Weight; Clozapine; Diabetes Mellitus, Type 2; Double-Bli | 2018 |
Effects of adjunctive metformin on metabolic traits in nondiabetic clozapine-treated patients with schizophrenia and the effect of metformin discontinuation on body weight: a 24-week, randomized, double-blind, placebo-controlled study.
Topics: Adult; Body Weight; Clozapine; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Metabol | 2013 |
Metformin for weight loss and metabolic control in overweight outpatients with schizophrenia and schizoaffective disorder.
Topics: Adult; Antipsychotic Agents; Body Mass Index; Dose-Response Relationship, Drug; Double-Blind Method; | 2013 |
Metformin for weight loss and metabolic control in overweight outpatients with schizophrenia and schizoaffective disorder.
Topics: Adult; Antipsychotic Agents; Body Mass Index; Dose-Response Relationship, Drug; Double-Blind Method; | 2013 |
Metformin for weight loss and metabolic control in overweight outpatients with schizophrenia and schizoaffective disorder.
Topics: Adult; Antipsychotic Agents; Body Mass Index; Dose-Response Relationship, Drug; Double-Blind Method; | 2013 |
Metformin for weight loss and metabolic control in overweight outpatients with schizophrenia and schizoaffective disorder.
Topics: Adult; Antipsychotic Agents; Body Mass Index; Dose-Response Relationship, Drug; Double-Blind Method; | 2013 |
The Relationships of Obesity-Related Genetic Variants With Metabolic Profiles and Response to Metformin in Clozapine-Treated Patients With Schizophrenia.
Topics: Adaptor Proteins, Signal Transducing; Adult; Aldose-Ketose Isomerases; Alleles; Antipsychotic Agents | 2015 |
Metformin treatment of antipsychotic-induced dyslipidemia: an analysis of two randomized, placebo-controlled trials.
Topics: Adult; Antipsychotic Agents; Blood Glucose; Body Weight; Double-Blind Method; Dyslipidemias; Female; | 2016 |
Effects of Low Dose Metformin on Metabolic Traits in Clozapine-Treated Schizophrenia Patients: An Exploratory Twelve-Week Randomized, Double-Blind, Placebo-Controlled Study.
Topics: Adult; Antipsychotic Agents; Body Mass Index; Body Weight; Clozapine; Double-Blind Method; Female; H | 2016 |
Effects of Low Dose Metformin on Metabolic Traits in Clozapine-Treated Schizophrenia Patients: An Exploratory Twelve-Week Randomized, Double-Blind, Placebo-Controlled Study.
Topics: Adult; Antipsychotic Agents; Body Mass Index; Body Weight; Clozapine; Double-Blind Method; Female; H | 2016 |
Effects of Low Dose Metformin on Metabolic Traits in Clozapine-Treated Schizophrenia Patients: An Exploratory Twelve-Week Randomized, Double-Blind, Placebo-Controlled Study.
Topics: Adult; Antipsychotic Agents; Body Mass Index; Body Weight; Clozapine; Double-Blind Method; Female; H | 2016 |
Effects of Low Dose Metformin on Metabolic Traits in Clozapine-Treated Schizophrenia Patients: An Exploratory Twelve-Week Randomized, Double-Blind, Placebo-Controlled Study.
Topics: Adult; Antipsychotic Agents; Body Mass Index; Body Weight; Clozapine; Double-Blind Method; Female; H | 2016 |
A randomized, double-blind, placebo-controlled trial of metformin treatment for weight gain associated with initiation of risperidone in children and adolescents.
Topics: Antipsychotic Agents; Child; Double-Blind Method; Humans; Hypoglycemic Agents; Metformin; Risperidon | 2008 |
Extended release metformin for metabolic control assistance during prolonged clozapine administration: a 14 week, double-blind, parallel group, placebo-controlled study.
Topics: Adult; Anthropometry; Antipsychotic Agents; Blood Glucose; Blood Pressure; Body Mass Index; Body Wei | 2009 |
Polymorphisms of the LEP- and LEPR genes, metabolic profile after prolonged clozapine administration and response to the antidiabetic metformin.
Topics: Adult; Antipsychotic Agents; Blood Glucose; Body Mass Index; Clozapine; Double-Blind Method; Female; | 2010 |
Assessment of treatment algorithms including amantadine, metformin, and zonisamide for the prevention of weight gain with olanzapine: a randomized controlled open-label study.
Topics: Adolescent; Adult; Aged; Algorithms; Amantadine; Antipsychotic Agents; Benzodiazepines; Clinical Pro | 2012 |
Metformin for treatment of antipsychotic-induced weight gain: a randomized, placebo-controlled study.
Topics: Adult; Antipsychotic Agents; Blood Glucose; Body Mass Index; Body Weight; Double-Blind Method; Femal | 2012 |
Metformin for treatment of antipsychotic-induced amenorrhea and weight gain in women with first-episode schizophrenia: a double-blind, randomized, placebo-controlled study.
Topics: Adolescent; Adult; Amenorrhea; Antipsychotic Agents; Blood Glucose; Body Mass Index; Body Weight; Do | 2012 |
Metformin for prevention of weight gain and insulin resistance with olanzapine: a double-blind placebo-controlled trial.
Topics: Adult; Anthropometry; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Diabetes Mellitus, Typ | 2006 |
Insulin counter-regulatory factors, fibrinogen and C-reactive protein during olanzapine administration: effects of the antidiabetic metformin.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Blood Glucose; C-Reactive Protein; Double-Blind Method | 2007 |
Metformin as an adjunctive treatment to control body weight and metabolic dysfunction during olanzapine administration: a multicentric, double-blind, placebo-controlled trial.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Blood Glucose; Body Mass Index; Body | 2007 |
Metformin for metabolic dysregulation in schizophrenic patients treated with olanzapine.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Body Weight; Female; Glucos | 2008 |
Lifestyle intervention and metformin for treatment of antipsychotic-induced weight gain: a randomized controlled trial.
Topics: Adult; Antipsychotic Agents; Blood Glucose; Body Mass Index; Double-Blind Method; Female; Humans; Hy | 2008 |
Lifestyle intervention and metformin for treatment of antipsychotic-induced weight gain: a randomized controlled trial.
Topics: Adult; Antipsychotic Agents; Blood Glucose; Body Mass Index; Double-Blind Method; Female; Humans; Hy | 2008 |
Lifestyle intervention and metformin for treatment of antipsychotic-induced weight gain: a randomized controlled trial.
Topics: Adult; Antipsychotic Agents; Blood Glucose; Body Mass Index; Double-Blind Method; Female; Humans; Hy | 2008 |
Lifestyle intervention and metformin for treatment of antipsychotic-induced weight gain: a randomized controlled trial.
Topics: Adult; Antipsychotic Agents; Blood Glucose; Body Mass Index; Double-Blind Method; Female; Humans; Hy | 2008 |
Metformin addition attenuates olanzapine-induced weight gain in drug-naive first-episode schizophrenia patients: a double-blind, placebo-controlled study.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Double-Blind Method; Drug | 2008 |
Metformin plus sibutramine for olanzapine-associated weight gain and metabolic dysfunction in schizophrenia: a 12-week double-blind, placebo-controlled pilot study.
Topics: Adult; Antipsychotic Agents; Appetite Depressants; Benzodiazepines; Body Mass Index; Chronic Disease | 2008 |
Metformin in obesity associated with antipsychotic drug administration: a pilot study.
Topics: Adult; Ambulatory Care; Antipsychotic Agents; Area Under Curve; Blood Glucose; Body Mass Index; Brie | 2001 |
23 other studies available for metformin and Schizophrenia
| Article | Year |
|---|---|
Clozapine induces metformin-resistant prediabetes/diabetes that is associated with poor clinical efficacy in patients with early treatment-resistant schizophrenia.
Topics: Antipsychotic Agents; Clozapine; Humans; Metformin; Prediabetic State; Prospective Studies; Schizoph | 2021 |
Metformin for the prevention of clozapine-induced weight gain: A retrospective naturalistic cohort study.
Topics: Adult; Antipsychotic Agents; Clozapine; Cohort Studies; Humans; Male; Metformin; Retrospective Studi | 2022 |
Risk of schizophrenia in patients with polycystic ovary syndrome: a nationwide population-based cohort study from Taiwan.
Topics: Cohort Studies; Female; Humans; Metformin; Polycystic Ovary Syndrome; Schizophrenia; Taiwan | 2021 |
Metformin attenuates antipsychotic-induced metabolic dysfunctions in MK801-induced schizophrenia-like rats.
Topics: Animals; Animals, Newborn; Antipsychotic Agents; Dizocilpine Maleate; Dose-Response Relationship, Dr | 2020 |
Interaction of clozapine with metformin in a schizophrenia rat model.
Topics: Animals; Behavior, Animal; Body Weight; Clozapine; Disease Models, Animal; Drug Interactions; Feedin | 2021 |
Metformin for antipsychotic-induced weight gain: Statistical curiosities.
Topics: Antipsychotic Agents; Exploratory Behavior; Humans; Hypoglycemic Agents; Metformin; Schizophrenia; W | 2017 |
Metformin reverses the schizophrenia-like behaviors induced by MK-801 in rats.
Topics: Animals; Antipsychotic Agents; Anxiety; Behavior, Animal; Cognition Disorders; Cognitive Dysfunction | 2019 |
Metformin for antipsychotic-related weight gain and metabolic abnormalities: when, for whom, and for how long?
Topics: Antipsychotic Agents; Female; Humans; Male; Metabolic Diseases; Metformin; Obesity; Psychotic Disord | 2013 |
Metformin and Alzheimer's disease risk.
Topics: Antipsychotic Agents; Female; Humans; Male; Metabolic Diseases; Metformin; Obesity; Psychotic Disord | 2014 |
Response to Rosenfeld.
Topics: Antipsychotic Agents; Female; Humans; Male; Metabolic Diseases; Metformin; Obesity; Psychotic Disord | 2014 |
Metformin for weight loss in schizophrenia: safe but not a panacea.
Topics: Antipsychotic Agents; Female; Humans; Male; Metabolic Diseases; Metformin; Obesity; Psychotic Disord | 2014 |
Metformin for treatment of antipsychotic-induced weight gain in a South Asian population with schizophrenia or schizoaffective disorder: A double blind, randomized, placebo controlled study.
Topics: Adult; Antipsychotic Agents; Blood Glucose; Body Mass Index; Body Weight; Double-Blind Method; Femal | 2015 |
Pancreatitis associated with metformin used for management of clozapine-related weight gain.
Topics: Adolescent; Antipsychotic Agents; Clozapine; Disease Management; Humans; Male; Metformin; Pancreatit | 2016 |
Metformin-induced acute dystonia in a schizophrenic patient treated with sulpiride and clozapine.
Topics: Antipsychotic Agents; Clozapine; Drug Interactions; Drug Therapy, Combination; Dystonia; Female; Hum | 2016 |
Considerations regarding the use of metformin with olanzapine.
Topics: Antipsychotic Agents; Benzodiazepines; Diabetes Mellitus, Type 2; Drug Administration Schedule; Huma | 2008 |
Olanzapine treatment and weight gain: considering the lipid side effects of antipsychotics.
Topics: Antipsychotic Agents; Asian People; Benzodiazepines; Energy Intake; Exercise; Humans; Hypoglycemic A | 2008 |
Metformin provides weight reduction for hospitalized patients receiving polypharmacy.
Topics: Adult; Antipsychotic Agents; Female; Hospitalization; Humans; Male; Metformin; Middle Aged; Overweig | 2010 |
Weight-reducing effects of metformin are sustained over 40 weeks for psychiatric inpatients receiving polypharmacy.
Topics: Exercise; Hospitalization; Hospitals, Psychiatric; Humans; Metformin; Obesity; Polypharmacy; Schizop | 2011 |
Metformin as a treatment for antipsychotic drug side effects: special focus on women with schizophrenia.
Topics: Amenorrhea; Antipsychotic Agents; Female; Humans; Hypoglycemic Agents; Metformin; Schizophrenia; Wei | 2012 |
Diabetes associated with atypical antipsychotic treatment may be severe but reversible: case report.
Topics: Adult; Antipsychotic Agents; Diabetes Mellitus, Type 2; Dibenzothiazepines; Female; Humans; Hypoglyc | 2005 |
Nutritional approach to metabolic changes arising out of schizophrenia therapy: case report.
Topics: Adult; Antipsychotic Agents; Behavior Therapy; Clozapine; Female; Humans; Insulin Resistance; Metfor | 2007 |
Antipsychotic-induced weight gain in patients with schizophrenia.
Topics: Antipsychotic Agents; Exercise; Humans; Hypoglycemic Agents; Insulin Resistance; Insulin-Like Growth | 2008 |
Cutting the Gordian knot. Addition of metformin to insulin therapy in a patient with uncontrolled diabetes and schizophrenia.
Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Insulin; | 1999 |